Astellas Pharma Inc. Sees U.S. Delay on Transplant Drug Advagraf

TOKYO (Reuters) - Japan's Astellas Pharma Inc said on Friday that U.S. authorities have requested more information on its key kidney transplant drug Advagraf, meaning it will face further delays in receiving approval there.